[1] Zimmermann S,Dziadziuszko R,Peters S.Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases[J].Cancer Treat Rev,2014, 40(6):716-722.
[2] Sperduto PW,Kased N,Roberge D,et al.Summary report on the graded prognostic assessment:an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases[J].J Clin Oncol,2012,30(4):419-425.
[3] Bailon O,Chouahnia K,Augier A,et al.Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma[J].Neuro Oncol,2012,14(4):491-495.
[4] Bearz A,Garassino I,Tiseo M,et al.Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer[J].Lung Cancer,2010,68(2):264-268.
[5] Barlesi F,Gervais R,Lena H,et al.Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)[J].Ann Oncol,2011,22(11): 2466-2470.
[6] Fan Y,Huang Z,Fang L,et al.Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer:survival analysis in 210 patients[J]. Onco Targets Ther,2013,6:1789-1803.
[7] Abbott NJ,Patabendige AA,Dolman DE,et al.Structure and function of the blood-brain barrier[J].Neurobiol Dis,2010,37(1):13-25.
[8] 蒲廷,靳雨,李光明,等.全脑放疗联合替莫唑胺治疗非小细胞肺癌脑转移的Meta分析[J].西部医学,2017,19(1):70-77.
[9] Chang EL,Wefel JS,Maor MH,et al.A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone[J]. Neurosurgery,2007,60(2):277-284.
[10] Andrews DW,Scott CB,Sperduto PW,et al.Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases:phase III results of the RTOG 9508 randomised trial[J].Lancet,2004,363(9422):1665-1672.
[11] 周麟,刘佳,卢铀.放疗在脑转移性肿瘤中的应用及其进展[J].中华放射肿瘤学杂志,2008,17(4):321-325.
[12] Tsao MN,Xu W,Wong RK,et al.Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases[J].Cochrane Database Syst Rev,2018,1:CD003869.
[13] Vecht CJ,Haaxma-Reiche H,Noordijk EM,et al.Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?[J].Ann Neurol,1993,33(6):583-590.
[14] Bradley KA,Mehta MP.Management of brain metastases[J].Semin Oncol,2004,31(5):693-701.
[15] Rosell R, Carcereny E, Gervais R, et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncol,2012, 13(3):239-246.
[16] Heon S,Yeap BY,Lindeman NI,et al.The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations[J].Clin Cancer Res,2012,18(16):4406-4414.
[17] Clarke JL,Pao W,Wu N,et al.High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer[J].J Neurooncol,2010,99(2):283-286.
[18] Grommes C,Oxnard GR,Kris MG,et al."Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer[J].Neuro Oncol,2011,13(12):1364-1369.
[19] Togashi Y,Masago K,Fukudo M,et al.Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation[J].Cancer Chemother Pharmacol,2011,68(4):1089-1092.
[20] Jenkins S,Yang JC,Ramalingam SS,et al.Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer[J].J Thorac Oncol,2017, 12(7): 1061-1070.
[21] Mok TS,Wu Y,Ahn M,et al.Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J].N Engl J Med,2017, 376(7):629-640.
[22] Vansteenkiste J,Reungwetwattana T,Nakagawa K,et al.CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC):Data from the FLAURA study[J].Ann Oncol,2017, 28(suppl 10).
[23] Aguiar PN Jr,Haaland B,Park W,et al.Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer[J].JAMA Oncol, 2018,4(8):1080-1084.
[24] Kaneda H,Okamoto I,Nakagawa K.Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer[J].J Thorac Oncol,2013,8(4): e32-e33.
[25] Maillet D,Martel-Lafay I,Arpin D,et al.Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement[J].J Thorac Oncol,2013, 8(4):e30-e31.
[26] Camidge DR,Kim DW,Tiseo M,et al.Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials[J].J Clin Oncol,2018,36(26):2693-2701.
[27] Sperduto PW,Berkey B,Gaspar LE,et al.A new prognostic index and comparison to three other indices for patients with brain metastases:an analysis of 1,960 patients in the RTOG database[J].Int J Radiat Oncol Biol Phys,2008,70(2):510-514.
[28] Gaspar L,Scott C,Rotman M,et al.Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials[J].Int J Radiat Oncol Biol Phys,1997,37(4):745-751. |
